Gainers

• Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session.
• GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding shares is at $1.8 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) stock rose 46.28% to $0.08. The company's market cap stands at $2.0 million.
• Corcept Therapeutics (NASDAQ:CORT) stock moved upwards by 19.93% to $111.48. The market value of their outstanding shares is at $9.9 billion. As per the press release, Q2 earnings came out yesterday.
• Mobile-health Network (NASDAQ:MNDR) stock moved upwards by 15.86% to $1.68. The company's market cap stands at $1.7 million.
• SL Science Holding (NASDAQ:SLBT) stock moved upwards by 15.38% to $3.0. The company's market cap stands at $1.4 billion.

Losers

• Capricor Therapeutics (NASDAQ:CAPR) stock fell 56.0% to $2.89 during Thursday's pre-market session.
• Inovio Pharmaceuticals (NASDAQ:INO) shares fell 21.31% to $0.82. The company's market cap stands at $85.5 million.
• Teladoc Health (NYSE:TDOC) shares fell 20.16% to $7.33. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q2 earnings came out yesterday.
• Pharming (NASDAQ:PHAR) shares declined by 16.74% to $10.0. The company's market cap stands at $848.2 million. As per the press release, Q2 earnings came out today.
• Biomerica (NASDAQ:BMRA) shares declined by 14.47% to $1.36. The market value of their outstanding shares is at $4.9 million.
• Advanced Biomed (NASDAQ:ADVB) stock decreased by 13.94% to $9.45. The market value of their outstanding shares is at $17.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.